Yang, C <br/><br/>
Rosiglitazone (BRL 49653) enhances insulin secretory response via phosphatidylinositol 3-kinase pathway.  [electronic resource] 

 -  Diabetes  Nov 2001 
 - 2598-602 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>0012-1797 
<br/><br/><label>Standard No.: </label>10.2337/diabetes.50.11.2598  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Animals<br/>Dose-Response Relationship, Drug<br/>Drug Synergism<br/>Glucose--pharmacology<br/>Hypoglycemic Agents--pharmacology<br/>In Vitro Techniques<br/>Insulin--metabolism<br/>Insulin Secretion<br/>Male<br/>Phosphatidylinositol 3-Kinases--physiology<br/>Rats<br/>Rats, Sprague-Dawley<br/>Rosiglitazone<br/>Thiazoles--pharmacology<br/>Thiazolidinediones